



# Kimia Biosciences Limited

Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana)

E-mail : [compliance.kimia@gmail.com](mailto:compliance.kimia@gmail.com) & [info@kimiabiosciences.com](mailto:info@kimiabiosciences.com)

Web : [www.kimiabiosciences.com](http://www.kimiabiosciences.com) | CIN NO. : L24239HR1993PLC032120

Tel. : +91 9654746544, 9654206544

KIMIABL/COMP/BSE/22-23/0011

Date: 30.05.2022

To,  
Corporate Relationship Department  
BSE Limited  
P.J. Towers  
1<sup>st</sup> Floor, New Trading Ring  
Dalal Street, Mumbai- 400001.

**Ref: BSE Scrip Code: 530313 and Scrip ID: KIMIABL**

**Sub: Outcome of Board Meeting**

Dear Sir/ Madam,

The meeting of the Board of Directors was held on Monday, May 30, 2022 at 4:00 pm (IST), and the following businesses, amongst others, were transacted thereat:

1. The resignation of Mr. Suneel Kapur as Chief Executive Officer of the Company was taken on record by the board of directors of the Company and has authorised Lakshay Prakash, Company Secretary & Compliance Officer to complete all requisite filings for the resignation of Mr. Suneel Kapur.
2. The matter of appointment of Mr. Sameer Goel as Chief Executive Officer was discussed and the board of directors approved the appointment of Mr. Sameer Goel as Chief Executive Officer of the Company.
3. Approval of audited financial results, on standalone basis, of the Company for the quarter and year ended March 31, 2022 in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taking on record the Independent Auditor's Report of the Auditors on the same (copy attached as **Annexure A**).
4. Approval of statements of standalone financial results of the Company for the quarter and year ended March 31, 2022, together with respective.
  - (i) Statement of Assets and Liabilities as on March 31, 2022 and
  - (ii) Statement of cash flow for the year ended March 31, 2022.

Page 1/2



# Kimia Biosciences Limited



Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana)  
E-mail : [compliance.kimia@gmail.com](mailto:compliance.kimia@gmail.com) & [info@kimiabiosciences.com](mailto:info@kimiabiosciences.com)  
Web : [www.kimiabiosciences.com](http://www.kimiabiosciences.com) | CIN NO. : L24239HR1993PLC032120  
Tel. : +91 9654746544, 9654206544

You are requested to take the above information on record and disseminate the same on your website.

The meeting concluded at 6.30 p.m.

Thanking you.

Yours faithfully,  
For Kimia Biosciences Limited

**Lakshay Prakash**  
Company Secretary & Compliance Officer



Place: New Delhi

**KIMIA BIOSCIENCES LIMITED**
**Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102**
**Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com**
**Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120**
**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022**

**₹ Lakhs except EPS**

S. No.	Particulars	Quarter ended			Year Ended	
		31/03/22	31/12/21	31/03/21	31/03/22	31/03/21
		(Audited Refer Note 2)	(Unaudited)	(Audited Refer Note 2)	(Audited)	(Audited)
I	Revenue from Operations	2,988.06	3,322.42	3,601.33	12,490.09	13,271.38
II	Other Income	21.90	21.79	47.10	93.22	245.62
III	<b>Total Income (I+II)</b>	<b>3,009.96</b>	<b>3,344.21</b>	<b>3,648.43</b>	<b>12,583.31</b>	<b>13,517.00</b>
IV	<b>Expenses:</b>					
	a) Cost of materials consumed	2,371.54	2,702.44	2,924.25	9,603.31	10,312.59
	b) Change in inventories of finished goods and work-in-progress	(96.76)	(146.91)	(99.28)	(376.96)	(627.22)
	c) Employee benefits expenses	368.90	405.39	378.62	1,508.05	1,409.10
	d) Finance costs	105.44	90.24	100.71	364.08	339.00
	e) Depreciation and amortisation expense	75.39	77.26	59.62	294.10	191.06
	f) Other expenses	380.44	396.36	405.94	1,692.55	1,339.03
V	<b>Total Expenses (IV)</b>	<b>3,204.95</b>	<b>3,524.78</b>	<b>3,769.86</b>	<b>13,085.13</b>	<b>12,963.56</b>
VI	<b>Profit/(loss) before tax (IV-V)</b>	<b>(194.99)</b>	<b>(180.57)</b>	<b>(121.43)</b>	<b>(501.82)</b>	<b>553.44</b>
VII	<b>Tax expenses:</b>					
	a) Current Tax	-	-	(4.50)	-	-
	b) Deferred Tax charge / (reversal)	(54.21)	(46.07)	(26.31)	(131.52)	43.00
VIII	<b>Profit/(loss) for the period (VI-VII)</b>	<b>(140.78)</b>	<b>(134.50)</b>	<b>(90.62)</b>	<b>(370.30)</b>	<b>510.44</b>
IX	<b>Other Comprehensive Income</b>					
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)					
	- Remeasurement of defined benefit plans	9.26	-	(3.99)	9.26	(3.99)
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-
X	<b>Total Comprehensive Income for the period (VIII+IX)</b>	<b>(131.52)</b>	<b>(134.50)</b>	<b>(94.61)</b>	<b>(361.04)</b>	<b>506.45</b>
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13
XII	<b>Other Equity</b>				<b>1,015.70</b>	<b>1,370.52</b>
XIII	<b>Earnings per equity share (not annualised)</b>					
	Basic in Rs.	(0.30)	(0.28)	(0.19)	(0.78)	1.08
	Diluted in Rs.	(0.30)	(0.28)	(0.19)	(0.78)	1.08



**KIMIA BIOSCIENCES LIMITED**

(Formerly known as Laurel Organics Limited)

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022****STATEMENT OF ASSETS, EQUITY and LIABILITIES**

S. No.	Particulars	As at 31-03-2022 (Audited)	As at 31-03-2021 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	Property, Plant & Equipment	3508.23	2827.25
	Capital Work-in-Progress	0.00	577.01
	Other Intangible Assets	14.48	9.52
	Deferred Tax Assets (Net)	90.83	-
	<b>Financial Assets</b>		
	(i) Other Non Current Financial Assets	20.28	17.28
	Other Non-current Assets	8.30	51.70
<b>2</b>	<b>Current Assets</b>		
	Inventories	3701.81	2368.72
	<b>Financial Assets</b>		
	(i) Investment	6.04	5.84
	(ii) Trade Receivables	3020.14	4176.57
	(iii) Cash and Cash Equivalents	20.49	58.66
	(iv) Bank balances other than (iii) above	31.24	108.73
	(v) Other Current Financial Assets	100.73	53.21
	Current Tax Assets (Net)	77.00	70.12
	Other Current Assets	349.57	172.09
	Non-Current Assets Classified as Held for Sale		170.20
	<b>Total Assets</b>	<b>10949.14</b>	<b>10666.90</b>
<b>B</b>	<b>EQUITY &amp; LIABILITIES</b>		
<b>1</b>	<b>EQUITY</b>		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	1015.70	1370.52
<b>2</b>	<b>NON CURRENT LIABILITIES</b>		
	<b>Financial Liabilities</b>		
	(i) Borrowings	2444.56	2834.63
	(ii) Other financial liabilities	488.77	448.41
	Deferred Tax Liabilities (Net)	-	43.80
	Provisions	112.07	116.94
	Other Non-Current Liabilities	234.73	284.66
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	<b>Financial Liabilities</b>		
	(i) Borrowings	1617.00	1658.36
	(ii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	19.10	21.10
	b. Total Outstanding due to other than Micro and Small Enterprises	4001.52	3057.53
	(iii) Other Financial Liabilities	313.00	262.54
	Provisions	5.16	5.29
	Other Current Liabilities	224.40	89.99
	<b>Total Equity and Liabilities</b>	<b>10949.14</b>	<b>10666.90</b>






**KIMIA BIOSCIENCES LIMITED**

(Formerly known as Laurel Organics Limited)

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022**

**STATEMENT OF CASH FLOWS**


Particulars	For the year ended	For the year ended
	March 31, 2022	March 31, 2021
	(Audited)	(Audited)
<b>A. Cash Flow from Operating Activities</b>		
Net Profit / (Loss) before tax	(501.82)	553.44
Adjustment for :		
Depreciation and amortization expense	294.10	191.06
Loss / (profit) on sale/discard of property, plant and equipment (net)	(7.92)	(3.70)
Finance costs	364.08	339.00
Gain on fair value of investment in mutual funds	(0.20)	(4.12)
Interest income	(3.11)	(5.36)
Deferred revenue income	(49.93)	(101.27)
Unrealised (gain)/loss on foreign currency transactions and translations	(1.43)	(58.77)
<b>Operating Profit Before Working Capital Changes</b>	<b>93.77</b>	<b>910.28</b>
Adjustments for:		
(Increase) / Decrease in inventories	(1,333.10)	(337.49)
(Increase)/ Decrease in trade and other receivables	925.05	(534.67)
Increase/ (Decrease) in trade and other payables	1,120.85	554.35
<b>Cash Generated From Operations</b>	<b>806.57</b>	<b>592.46</b>
Less : Income tax paid/ (refunds)	(6.89)	4.24
<b>Net Cash From Operating Activities</b>	<b>799.68</b>	<b>596.70</b>
<b>B. Cash Flow from Investment Activities</b>		
Purchases of property, plant and equipments including intangible assets & capital advances	(357.98)	(1,356.08)
Proceeds from sales of property, plant & equipment	206.67	5.04
Net inflow / (outflow) in fixed deposits	77.49	(54.59)
Proceeds from sales of current investments	-	39.99
Interest received	2.79	5.36
<b>Net Cash Used In Investing Activities</b>	<b>(71.03)</b>	<b>(1,360.27)</b>
<b>C. Cash Flow from Financing Activities</b>		
Receipts from non current borrowings	1,234.27	1,665.60
Repayment of non current borrowings	(1,509.87)	(1,299.34)
Net proceeds of current borrowings	(155.83)	680.64
Finance costs paid	(335.39)	(247.85)
<b>Net Cash Used in Financing Activities</b>	<b>(766.82)</b>	<b>799.05</b>
<b>Net Increase/(Decrease ) in Cash and Cash Equivalents</b>	<b>(38.17)</b>	<b>35.48</b>
Cash and Cash Equivalents at the beginning of the period	58.66	23.18
<b>Cash and Cash Equivalents at the end of the period</b>	<b>20.49</b>	<b>58.66</b>

**Other Notes**

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for three months ended March 31,2022 and March 31, 2021 are the balancing figure between audited figures in respect of the full financial year and published year to date figures up to the nine months of the current financial year. The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 30, 2022

Date : May 30, 2022  
Place : New Delhi

FOR KIMIA BIOSCIENCES LIMITED



*Sameer Goel*  
Sameer Goel  
(Managing Director)  
DIN - 00161786

## **Independent Auditor's Report on the Quarterly and Annual Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To the Board of Directors of Kimia Biosciences Limited

### **Report on the Audit of the Financial Results**

#### **Opinion**

We have audited the accompanying statement of quarterly and annual financial results of Kimia Biosciences Limited ("the Company"), for the quarter and year ended March 31, 2022 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement read with notes therein:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income for the quarter and year ended March 31, 2022 and other financial information of the Company for the quarter and year ended March 31, 2022.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion.

#### **Management's Responsibilities for the Financial Results**

These financial results have been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.





# Singhi & Co.

Chartered Accountants

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matter

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Date : May 30, 2022

Place : Noida (Delhi – NCR)



For Singhi & Co.  
Chartered Accountants  
Firm Reg. No. 302049E

A handwritten signature in blue ink, appearing to be "Bimal Kumar Sipani".

Bimal Kumar Sipani  
Partner

Membership No. 088926

UDIN : 22088926AJXKVY2420